SCHEMBL2492860

SCHEMBL2492860

CCCCCCCCCCCCCCCC(CC)C(=O)O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.83
MAPK1 P28482 1/20 0.83
GRIK1 P39086 2/20 0.63
GRIK2 Q13002 2/20 0.63
SLC1A2 P43004 2/20 0.60
SLC1A1 P43005 2/20 0.60
GPR84 Q9NQS5 5/20 0.59
FFAR1 O14842 1/20 0.59
MAPT P10636 1/20 0.57
LCK P06239 1/20 0.57
PPARD Q03181 1/20 0.57
ZDHHC20 Q5W0Z9 1/20 0.57
ZDHHC2 Q9UIJ5 1/20 0.57
CA1 P00915 1/20 0.54
ACE2 Q9BYF1 1/20 0.53
CHRM1 P11229 1/20 0.52
AKR1A1 P14550 1/20 0.52
CHRM3 P20309 1/20 0.52
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167273 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL10788879 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL687840 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL1704587 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
Hexane SCHEMBL4788148 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL249553 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL17329112 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
Hexane SCHEMBL18237384 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL3003696 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL1645242 1.00 CA2 (0.83) CA2MAPK1GRIK1GRIK2SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3661600-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME Epitracker, Inc. (US) 2020-06-10 EP claimed
EP-2644185-B1 THICK CLEANING COMPOSITION SUZHOU ELECO CHEMICAL IND CO LTD (CN) 2018-04-25 EP claimed
CN-103338743-B A kind of Cleasing compositions of stiff SUZHOU YUANSUJI CHEMICAL INDUSTRY Co.,Ltd. (CN) 2016-06-01 CN claimed
EP-2644185-A1 THICK CLEANING COMPOSITION Suzhou Yuansuji Chemical Industry Co., Ltd. (CN) 2013-10-02 EP claimed
US-20130251648-A1 THICK CLEANING COMPOSITION SUZHOU YUANSUJI CHEMICAL INDUSTRY CO., LTD. (CN) 2013-09-26 US claimed
US-20260048037-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN EPITRACKER INC (US) 2026-02-19 US disclosed
EP-4692226-A1 SOLUTION, DISPERSANT, METHOD FOR PRODUCING VINYL COMPOUND POLYMER, AND METHOD FOR PRODUCING SOLUTION Kuraray Co., Ltd. (JP) 2026-02-11 EP disclosed
EP-4674910-A1 COMPOSITION COMPRISING VINYL ALCOHOL-BASED POLYMER, AND METHOD FOR SEPARATING VINYL ALCOHOL-BASED POLYMER Kuraray Co., Ltd. (JP) 2026-01-07 EP disclosed
US-12440473-B2 Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain Epitracker, Inc. (US) 2025-10-14 US disclosed
CN-117925729-B Transfection reagent based on blank lipid nano-particles, preparation method and application thereof 晟迪生物医药(苏州)有限公司 2025-06-10 CN disclosed
CN-117919199-B Application of blank lipid nanoparticles in preparation of in-vivo delivery products 晟迪生物医药(苏州)有限公司 2025-05-13 CN disclosed
CN-119970539-A Active ingredient dissolving composition 苏州元素集化学工业有限公司 2025-05-13 CN disclosed
CN-1678566-A Novel acyl-containing compositions ASAHI CHEMICAL CORP (JP) 2005-10-05 CN disclosed
EP-1547998-A1 NOVEL COMPOSITION CONTAINING ACYL GROUP Asahi Kasei Chemicals Corporation (JP) 2005-06-29 EP disclosed
US-6569829-B1 Removing impurities from a long chain N-acyl acidic amino acid such as N-lauroyl-L-glutamic acid containing an inorganic salt by solvent extraction using a solution of water and tert-butanol; use in cosmetics and detergents ASAHI KASEI KABUSHIKI KAISHA (JP) 2003-05-27 US disclosed
CN-1345335-A Melanocortin receptor ligands PROCTER & GAMBLE (US) 2002-04-17 CN disclosed
CN-1332721-A Process for producing acidic N-long chain acylamino acid ASAHI CHEMICAL IND (JP) 2002-01-23 CN disclosed
EP-1156033-A1 PROCESS FOR PRODUCING ACIDIC N-(LONG-CHAIN ACYL)AMINO ACID Asahi Kasei Kabushiki Kaisha (JP) 2001-11-21 EP disclosed
EP-0351428-A1 COMPOSITIONS AND LUBRICANTS AND FUNCTIONAL FLUIDS CONTAINING SAME The Lubrizol Corporation (US) 1990-01-24 EP disclosed
US-4424245-A LEUCO DYE, ACID, WAX, POLYMER BARRIER RICOH COMPANY, LTD. (JP) 1984-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048037-A1 FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN CNR1, CNR2, FFAR1 CA2 1555/4885MAPK1 1044/4885GRIK1 132/4885
US-12440473-B2 Fatty acid analogs and their use in the treatment of cognitive impairment, behavioral conditions, and chronic pain SCD, FABP7, ELOVL1 CA2 2576/4885MAPK1 2881/4885GRIK1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.